生物标志物 生物标志物
Drew Butkowski1, Ronald B DeMattos2, Sergey Shcherbinin2
1Eli Lilly, Indanapolis, IN, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
这项研究建立了donanemab生理学基础的药理动力学 (PBPK) 模型,以模拟早期症状性阿尔茨海默病 (AD) 的粉样斑减少. 该模型预测,donanemab治疗有效地通过维持目标间歇性液体 (ISF) 度来降低大脑粉样质斑块水平.
科学领域:
- 药理动力学和药理动力学
- 神经退行性疾病 神经退行性疾病
- 药物开发 药物开发
背景情况:
- 基于生理学的药理动力学 (PBPK) 模型模拟了抗体治疗药物的处置在中枢神经系统 (CNS),包括脑脊髓 (CSF) 和间歇液体 (ISF).
- 这些模型可以预测粉样蛋白聚合动态和治疗效果.
- 多纳尼马布是一种针对N3pGβ-粉样蛋白的IgG1抗体,适用于早期症状性阿尔茨海默病 (AD).
研究的目的:
- 建立一个与粉样斑块生命周期模型集成的donanemab PBPK模型.
- 为了确定donanemab的目标ISF度.
- 预测多纳尼马布剂量方案对大脑粉样质斑块水平的影响.
主要方法:
- 一个纵向的自然生命周期模型的粉样蛋白聚合被开发为早期症状阿尔茨海默病的参与者.
- 该模型评估了donanemab在目标ISF度下对粉样蛋白聚合的影响.
- 分析了多纳尼马布在早期症状AD的第一,第二和第三阶段研究 (N=2560) 的数据.
主要成果:
- 年龄和APOE4基因型显著影响粉样蛋白聚合,大约在60岁左右,CSF/ISFAβ42和血Aβ42/Aβ40比率下降.
- 粉样蛋白斑块水平在60岁左右增加,在更高年龄时和,在APOE4载体中较早出现.
- 在早期有症状的AD患者 (平均年龄73.2岁) 中,当维持血清度>15微克/毫升,与相应的CSF和ISF水平时,多纳尼马布治疗实现了强大的粉样质斑减少.
结论:
- 了解粉胺向剂的中枢神经系统排放,可以提高对治疗性ISF度的理解.
- 多纳尼马布PBPK/粉状斑块模型为优化剂量策略提供了一个工具.
- 这种建模方法支持开发阿尔茨海默病的有效治疗方法.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516